ENDMC
MCID: END057
MIFTS: 75

Endometrial Cancer (ENDMC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Endometrial Cancer

Aliases & Descriptions for Endometrial Cancer:

Name: Endometrial Cancer 54 50 66 13 52
Endometrial Carcinoma 12 29 13 52 14 69
Endometrial Carcinoma, Somatic 54 24
Carcinoma, Endometrioid 42 69
Endometrial Neoplasms 42 69
Endometrioid Carcinoma of Female Reproductive System 12
Malignant Neoplasm of Endometrium 69
Endometrial Cancer, Familial 54
Carcinoma of the Endometrium 12
Endometrioid Carcinoma 12
Uterine Corpus Cancer 69
Endmc 66

Classifications:



External Ids:

OMIM 54 608089
Disease Ontology 12 DOID:2871
NCIt 47 C3769 C7558
MedGen 40 C0476089
ICD10 33 C54.1

Summaries for Endometrial Cancer

UniProtKB/Swiss-Prot : 66 Endometrial cancer: A malignancy of endometrium, the mucous lining of the uterus. Most endometrial cancers are adenocarcinomas, cancers that begin in cells that make and release mucus and other fluids.

MalaCards based summary : Endometrial Cancer, also known as endometrial carcinoma, is related to pyomyositis and colorectal cancer, and has symptoms including endometrial carcinoma An important gene associated with Endometrial Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Levonorgestrel and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and lymph node, and related phenotypes are Decreased viability and cellular

Disease Ontology : 12 A endometrial cancer that is located in the tissue lining the uterus.

Wikipedia : 71 Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It... more...

Description from OMIM: 608089

Related Diseases for Endometrial Cancer

Diseases related to Endometrial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
id Related Disease Score Top Affiliating Genes
1 pyomyositis 30.3 CDH1 EGFR ERBB2 ESR1 PGR TP53
2 colorectal cancer 30.3 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
3 uterine corpus endometrial carcinoma 11.8
4 lynch syndrome 11.4
5 polycystic ovary syndrome 11.2
6 poorly differentiated endocrine carcinoma of the corpus uteri 11.0
7 endometrial adenosquamous carcinoma 11.0
8 precocious puberty, central, 2 10.8
9 precocious puberty, central, 1 10.8
10 endometrioid ovary carcinoma 10.8
11 glioma 10.6 ERBB2 ESR1 PGR
12 large intestine adenoma 10.6 MLH1 MSH2 MSH6
13 benign fibrous mesothelioma 10.5 EGF ESR1 MLH1 MSH2 MSH6
14 central nervous system mature teratoma 10.5 ERBB2 ESR1 PGR TP53
15 postpartum depression 10.5 ERBB2 ESR1 PGR TP53
16 cervical lymphoepithelioma-like carcinoma 10.5 EGFR ERBB2 ESR1 PGR
17 polyembryoma of the ovary 10.5 ERBB2 ESR1 PGR PTEN
18 nervous system hibernoma 10.5 EGFR ERBB2 ESR1 PGR
19 male reproductive organ benign neoplasm 10.5 ERBB2 ESR1 PGR TP53
20 central nervous system primitive neuroectodermal neoplasm 10.5 ERBB2 ESR1 PGR TP53
21 villoglandular endometrial endometrioid adenocarcinoma 10.5 CCND1 ESR1 PGR PTEN TP53
22 fallopian tube carcinosarcoma 10.5 ERBB2 ESR1 PGR TP53
23 fibromatosis, gingival, 1 10.5 CTNNB1 MLH1 MSH2 MSH6 PTEN
24 basaloid squamous cell carcinoma 10.5 CDH1 EGFR ERBB2 PGR
25 anomalous left coronary artery from the pulmonary artery 10.5 EGFR ERBB2 ESR1 PGR
26 histiocytic and dendritic cell cancer 10.5 ERBB2 ESR1 PGR
27 arthus reaction 10.5 ERBB2 ESR1 KRAS PGR TP53
28 breast ductal carcinoma 10.5 CTNNB1 KRAS PGR PTEN TP53
29 wolffian duct adenoma 10.5 KRAS MLH1 MSH2 MSH6
30 combined t cell and b cell immunodeficiency 10.5 CDH1 EGFR ERBB2 ESR1 PGR
31 neuroretinitis 10.5 CCND1 KRAS MLH1 MSH2 MSH6
32 vulva adenocarcinoma 10.5 ERBB2 ESR1 PGR TP53
33 uterine corpus endometrial stromal sarcoma 10.5 KRAS MLH1 PIK3CA TP53
34 anus adenocarcinoma 10.5 EGFR ERBB2 ESR1 PGR
35 triple-receptor negative breast cancer 10.5 EGFR ERBB2 PGR
36 sclerosing hemangioma 10.5 CDH1 EGFR ERBB2 ESR1 PGR
37 skin sarcoma 10.5 EGFR ERBB2 PGR
38 retinal disease 10.5 CDH1 EGFR ERBB2 ESR1 PGR
39 congenital bile acid synthesis defect 10.5 ERBB2 ESR1 PGR TP53
40 larynx liposarcoma 10.5 MLH1 MSH2 PTEN TP53
41 metagonimiasis 10.5 ERBB2 ESR1 PGR TP53
42 allergic contact dermatitis 10.5 EGFR KRAS MLH1 TP53
43 adult syndrome 10.5 CTNNB1 KRAS PIK3CA PTEN TP53
44 immunodeficiency due to a late component of complement deficiency 10.5 EGFR ERBB2 PGR TP53
45 trypanosomiasis 10.5 MLH1 MSH3 MSH6
46 benign shuddering attacks 10.5 CDH1 ESR1 KRAS MLH1 TP53
47 retroperitoneal neuroblastoma 10.5 KRAS PIK3CA PTEN TP53
48 fibrolamellar carcinoma 10.5 CTNNB1 MLH1 MSH2
49 aorta atresia 10.5 EGF MLH1 MSH2
50 adult central nervous system mature teratoma 10.5 CCND1 ERBB2 TP53

Graphical network of the top 20 diseases related to Endometrial Cancer:



Diseases related to Endometrial Cancer

Symptoms & Phenotypes for Endometrial Cancer

Clinical features from OMIM:

608089

Human phenotypes related to Endometrial Cancer:

32
id Description HPO Frequency HPO Source Accession
1 endometrial carcinoma 32 HP:0012114

GenomeRNAi Phenotypes related to Endometrial Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.7 KRAS PIK3CA EGFR
2 Decreased viability GR00106-A-0 10.7 KRAS
3 Decreased viability GR00107-A-1 10.7 TGFBR2
4 Decreased viability GR00221-A-1 10.7 KRAS PIK3CA TGFBR2 CDH1 EGFR ESR1
5 Decreased viability GR00221-A-2 10.7 ESR1 KRAS PIK3CA
6 Decreased viability GR00221-A-3 10.7 TGFBR2 ERBB2
7 Decreased viability GR00221-A-4 10.7 ESR1 PIK3CA TGFBR2 EGFR ERBB2
8 Decreased viability GR00301-A 10.7 KRAS CDH1 MLH3 MSH2
9 Decreased viability GR00381-A-1 10.7 KRAS
10 Decreased viability in esophageal squamous lineage GR00235-A 10.03 ERBB2 ESR1 KRAS MLH1 PGR PIK3CA
11 Increased cell death HMECs cells GR00103-A-0 9.7 CTNNB1 EGFR PGR PIK3CA PTEN TGFBR2
12 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.35 CCND1 ESR1 ESR2 MSH2 PTEN
13 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.17 MLH1 MLH3 MSH2 MSH3 MSH6 MUTYH

MGI Mouse Phenotypes related to Endometrial Cancer:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.57 CCND1 CDH1 CTNNB1 EGFR ERBB2 ESR1
2 homeostasis/metabolism MP:0005376 10.51 PGR PIK3CA PTEN TGFBR2 TP53 CCND1
3 endocrine/exocrine gland MP:0005379 10.49 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
4 digestive/alimentary MP:0005381 10.47 CTNNB1 EGF EGFR ERBB2 ESR1 ESR2
5 integument MP:0010771 10.47 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
6 mortality/aging MP:0010768 10.45 ESR1 ESR2 KRAS MLH1 MSH2 MSH3
7 cardiovascular system MP:0005385 10.43 PGR PIK3CA PTEN TGFBR2 TP53 CCND1
8 neoplasm MP:0002006 10.41 MLH1 MSH2 MSH3 MSH6 MUTYH PGR
9 behavior/neurological MP:0005386 10.4 CCND1 CTNNB1 ERBB2 ESR1 ESR2 KRAS
10 growth/size/body region MP:0005378 10.39 CTNNB1 EGF EGFR ERBB2 ESR1 ESR2
11 immune system MP:0005387 10.39 CCND1 CDH1 CTNNB1 EGF EGFR ESR1
12 embryo MP:0005380 10.33 CDH1 CTNNB1 EGFR ERBB2 ESR1 KRAS
13 hematopoietic system MP:0005397 10.31 CCND1 CTNNB1 EGFR ESR1 ESR2 KRAS
14 nervous system MP:0003631 10.25 CCND1 CTNNB1 EGFR ERBB2 ESR1 ESR2
15 muscle MP:0005369 10.22 CTNNB1 EGFR ERBB2 ESR1 ESR2 KRAS
16 limbs/digits/tail MP:0005371 10.18 CTNNB1 EGFR ERBB2 ESR1 ESR2 KRAS
17 normal MP:0002873 10.18 CCND1 CDH1 CTNNB1 EGF EGFR ERBB2
18 adipose tissue MP:0005375 10.17 EGFR ESR1 ESR2 PIK3CA PTEN TGFBR2
19 craniofacial MP:0005382 10.15 CCND1 CTNNB1 EGFR ERBB2 KRAS TGFBR2
20 reproductive system MP:0005389 10.13 MLH1 MLH3 PGR PIK3CA PTEN TP53
21 liver/biliary system MP:0005370 10.11 PTEN TGFBR2 TP53 CTNNB1 EGFR ESR1
22 no phenotypic analysis MP:0003012 10.06 CDH1 CTNNB1 EGFR ESR1 ESR2 KRAS
23 respiratory system MP:0005388 9.9 EGFR ERBB2 ESR1 ESR2 KRAS MLH1
24 skeleton MP:0005390 9.73 PTEN TGFBR2 TP53 CCND1 CTNNB1 EGFR
25 pigmentation MP:0001186 9.72 CTNNB1 EGFR KRAS PTEN TP53
26 vision/eye MP:0005391 9.32 MLH1 PIK3CA PTEN TGFBR2 TP53 CCND1

Drugs & Therapeutics for Endometrial Cancer

Drugs for Endometrial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 448)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2 797-63-7, 17489-40-6 13109
2
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 50-28-2 5757 53477783
4
Ethinyl Estradiol Approved Phase 4,Phase 2 57-63-6 5991
5
Norethindrone Approved Phase 4,Phase 2 68-22-4 6230
6
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 57-83-0 5994
7
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 112809-51-5 3902
8
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
9
Megestrol acetate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 595-33-5 11683
10
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
11
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
12
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
13
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
14
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
18
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
19
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
20
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
21 Dienogest Approved Phase 4 65928-58-7
22
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
23
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
25
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1 58-05-9 54575, 6560146 143
26 tannic acid Approved, Nutraceutical Phase 4,Phase 2
27
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
28
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
29
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
30
Enclomiphene Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 15690-57-0
31 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Contraceptive Agents, Male Phase 4,Phase 3,Phase 2
34 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Phase 1
35 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38
Medroxyprogesterone Phase 4,Phase 3,Phase 2 520-85-4 10631
39 Progestins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3,Early Phase 1
41 Estradiol 3-benzoate Phase 4,Phase 2,Phase 3,Early Phase 1
42 Estradiol valerate Phase 4,Phase 2,Phase 3,Early Phase 1 979-32-8
43 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Polyestradiol phosphate Phase 4,Phase 2,Phase 3,Early Phase 1
45 Norethindrone acetate Phase 4,Phase 2
46 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
47 Norinyl Phase 4
48 Phytoestrogens Phase 4,Phase 3,Phase 2,Phase 1
49 Anticoagulants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 845)
id Name Status NCT ID Phase
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4
3 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Unknown status NCT01074892 Phase 4
4 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
5 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment Completed NCT00190697 Phase 4
6 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4
7 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4
8 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed NCT01048606 Phase 4
9 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4
10 The Effect of Ethinyl Estradiol on Polycystic Ovary Syndrome Women Undergoing Intrauterine Insemination Completed NCT01219101 Phase 4
11 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4
12 Letrozole Versus Clomifene Citrate for Ovulation Induction Completed NCT00478504 Phase 4
13 Role of Melatonin Supplementation in Follicular Fluid of in Vitro Fertilization (IVF) Patients With Polycystic Ovarian Syndrome Completed NCT01540747 Phase 4
14 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
15 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4
16 Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer Recruiting NCT02344940 Phase 4
17 HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients Recruiting NCT02273791 Phase 4
18 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4
19 Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS Recruiting NCT02344888 Phase 4
20 Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS Recruiting NCT02436226 Phase 4
21 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Active, not recruiting NCT02866786 Phase 4
22 Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines Not yet recruiting NCT03164590 Phase 4
23 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Not yet recruiting NCT02440750 Phase 4
24 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Not yet recruiting NCT02601196 Phase 4
25 Pharmacokinetics and Safety of Transdermal Megestrol Acetate Withdrawn NCT00163072 Phase 4
26 Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate Withdrawn NCT01966575 Phase 4
27 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Unknown status NCT01820858 Phase 3
28 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies Unknown status NCT00726635 Phase 3
29 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
30 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
31 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
32 Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause Unknown status NCT00925639 Phase 3
33 Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet. Unknown status NCT01414517 Phase 3
34 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
35 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
36 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
37 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
38 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
39 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
40 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
41 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
42 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
43 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
44 Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Completed NCT00003691 Phase 3
45 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
46 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
47 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
48 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed NCT01767155 Phase 3
49 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
50 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3

Search NIH Clinical Center for Endometrial Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: endometrial neoplasms

Genetic Tests for Endometrial Cancer

Genetic tests related to Endometrial Cancer:

id Genetic test Affiliating Genes
1 Endometrial Carcinoma 29
2 Endometrial Neoplasm 29
3 Endometrial Carcinoma, Somatic 24 MSH3

Anatomical Context for Endometrial Cancer

MalaCards organs/tissues related to Endometrial Cancer:

39
Uterus, Breast, Lymph Node, Endothelial, Testes, Lung, Colon

The Foundational Model of Anatomy Ontology organs/tissues related to Endometrial Cancer:

18
The Tissue Lining The Uterus

Publications for Endometrial Cancer

Articles related to Endometrial Cancer:

(show top 50) (show all 1470)
id Title Authors Year
1
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. ( 28532857 )
2017
2
Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). ( 28058740 )
2017
3
Evaluating Myometrial Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging. ( 28515411 )
2017
4
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. ( 28055301 )
2017
5
Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. ( 28062022 )
2017
6
Magnetic Resonance Diffusion-Weighted Imaging: Endometrial Cancer. ( 28063889 )
2017
7
Supervised Clustering of Adipokines and Hormonal Receptors Predict Prognosis in a Population of Obese Women with Type 1 Endometrial Cancer. ( 28505082 )
2017
8
miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. ( 28178620 )
2017
9
Risk factors for paraaortic lymph node metastasis in endometrial cancer. ( 28523533 )
2017
10
Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. ( 28232485 )
2017
11
Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative. ( 28511869 )
2017
12
Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. ( 28067948 )
2017
13
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. ( 28528918 )
2017
14
Population-based cohort study of the effect of endometrial cancer classification and treatment criteria on long-term survival. ( 28504819 )
2017
15
Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. ( 28339086 )
2017
16
Definitive three-dimensional high-dose-rate brachytherapy for inoperable endometrial cancer. ( 28533799 )
2017
17
Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer. ( 28083737 )
2017
18
Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60). ( 28516398 )
2017
19
Point: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging? ( 28516437 )
2017
20
EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. ( 28088786 )
2017
21
Minimally Invasive Staging Surgery in Women with Early-Stage Endometrial Cancer: Analysis of the National Cancer Data Base. ( 28074326 )
2017
22
Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome: A French Multicenter Study. ( 28525912 )
2017
23
National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. ( 28525495 )
2017
24
Case Report of Menopausal Woman Diagnosed with Endometrial Cancer after Colon Cancer with Germline Mutation in MSH6 in Korea. ( 28523262 )
2017
25
Omitting lymphadenectomy in patients with endometrial cancer. ( 28067947 )
2017
26
Differential expression of ten-eleven translocation genes in endometrial cancers. ( 28349832 )
2017
27
Comparison of lifestyle, hormonal and medical factors in women with sporadic and Lynch syndrome-associated endometrial cancer: A retrospective case-case study. ( 28529751 )
2017
28
Current strategies in the diagnosis of endometrial cancer. ( 28508342 )
2017
29
Lynch Syndrome and Endometrial Cancer. ( 28376523 )
2017
30
Loss of tricellular tight junction protein LSR promotes cell invasion and migration via upregulation of TEAD1/AREG in human endometrial cancer. ( 28071680 )
2017
31
Counterpoint: Is Lymphadenectomy Required in Endometrial Cancer for Adequate Surgical Staging? ( 28516438 )
2017
32
Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort. ( 28069268 )
2017
33
Detection of recurrence in early stage endometrial cancer - the role of symptoms and routine follow-up. ( 28080157 )
2017
34
Triple negative endometrial cancer. ( 28509323 )
2017
35
Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group. ( 28058558 )
2017
36
Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. ( 28078189 )
2017
37
Minimally Invasive Approach in Type II endometrial cancer: it is wise and safe? ( 28065812 )
2017
38
Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. ( 28526167 )
2017
39
RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer. ( 28528974 )
2017
40
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. ( 28061006 )
2017
41
Patients with endometrial cancer at risk for lymphatic metastasis should undergo pelvic and periaortic lymphadenectomy as part of their initial surgery. ( 28067950 )
2017
42
Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway. ( 28521459 )
2017
43
The gate-keeping role of surgeons with regard to endometrial cancers in Lynch syndrome. ( 27894169 )
2017
44
Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy. ( 26588239 )
2016
45
Clinical Significance of Serum Interleukin-31 and Interleukin-33 Levels in Patients of Endometrial Cancer: A Case Control Study. ( 27340318 )
2016
46
L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. ( 27648714 )
2016
47
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal Adhesion Kinase Activity (FAK) and miRNA-200a. ( 27497669 )
2016
48
Biglycan enhances the ability of migration and invasion in endometrial cancer. ( 26275380 )
2016
49
Big Data to the Rescue: Is there a benefit to combined-modality adjuvant therapy in endometrial cancer? ( 27210265 )
2016
50
Paraneoplastic cerebellar degeneration and endometrial cancer: a rare occurrence. ( 27020505 )
2016

Variations for Endometrial Cancer

UniProtKB/Swiss-Prot genetic disease variations for Endometrial Cancer:

66
id Symbol AA change Variation ID SNP ID
1 PTEN p.His123Tyr VAR_026260 rs786204931

ClinVar genetic disease variations for Endometrial Cancer:

6 (show all 12)
id Gene Variation Type Significance SNP ID Assembly Location
1 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
2 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic rs36053993 GRCh37 Chromosome 1, 45797228: 45797228
3 MLH3 MLH3, 1-BP DEL, 885G deletion Pathogenic
4 PTEN NM_000314.6(PTEN): c.253+1G> A single nucleotide variant Pathogenic rs587776667 GRCh37 Chromosome 10, 89690847: 89690847
5 MSH3 NM_002439.4(MSH3): c.1148delA (p.Lys383Argfs) deletion Pathogenic rs587776701 GRCh38 Chromosome 5, 80675103: 80675103
6 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
7 KRAS NM_004985.4(KRAS): c.40G> A (p.Val14Ile) single nucleotide variant Pathogenic rs104894365 GRCh37 Chromosome 12, 25398279: 25398279
8 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
9 FGFR2 NM_000141.4(FGFR2): c.1124A> G (p.Tyr375Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913478 GRCh37 Chromosome 10, 123274794: 123274794
10 FGFR2 NM_000141.4(FGFR2): c.1115C> G (p.Ser372Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913477 GRCh37 Chromosome 10, 123274803: 123274803
11 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
12 MSH6 NM_000179.2(MSH6): c.2731C> T (p.Arg911Ter) single nucleotide variant Pathogenic rs63751017 GRCh37 Chromosome 2, 48027853: 48027853

Cosmic variations for Endometrial Cancer:

9 (show top 50) (show all 642)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10654 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.637C>T p.R213* 12
2 COSM11582 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.395A>G p.K132R 12
3 COSM10704 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.844C>T p.R282W 12
4 COSM43768 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.700T>G p.Y234D 12
5 COSM10690 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.473G>A p.R158H 12
6 COSM46074 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.604C>T p.R202C 12
7 COSM10659 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.817C>T p.R273C 12
8 COSM10660 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.818G>A p.R273H 12
9 COSM6932 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.733G>A p.G245S 12
10 COSM43663 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.826G>C p.A276P 12
11 COSM10648 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.524G>A p.R175H 12
12 COSM43766 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.899C>T p.P300L 12
13 COSM44130 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.477C>T p.A159A 12
14 COSM43632 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.493C>T p.Q165* 12
15 COSM10656 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.742C>T p.R248W 12
16 COSM11090 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.541C>T p.R181C 12
17 COSM43753 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.560-1G>A p.? 12
18 COSM43765 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.727A>C p.M243L 12
19 COSM10705 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.586C>T p.R196* 12
20 COSM10742 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.578A>G p.H193R 12
21 COSM43837 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.843C>G p.D281E 12
22 COSM10662 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.743G>A p.R248Q 12
23 COSM10663 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.916C>T p.R306* 12
24 COSM96339 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.993G>T p.Q331H 12
25 COSM43708 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.422G>A p.C141Y 12
26 COSM11183 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.799C>T p.R267W 12
27 COSM43906 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.843C>A p.D281E 12
28 COSM45268 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.827C>A p.A276D 12
29 COSM43684 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.720T>G p.S240R 12
30 COSM10808 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.488A>G p.Y163C 12
31 COSM3970361 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.472C>A p.R158S 12
32 COSM10889 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.536A>G p.H179R 12
33 COSM10735 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.638G>A p.R213Q 12
34 COSM43714 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.836G>A p.G279E 12
35 COSM11305 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.809T>C p.F270S 12
36 COSM10709 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.722C>G p.S241C 12
37 COSM11483 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.848G>A p.R283H 12
38 COSM303910 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.691A>C p.T231P 12
39 COSM43767 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.406C>G p.Q136E 12
40 COSM11196 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.734G>T p.G245V 12
41 COSM10788 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.764T>G p.I255S 12
42 COSM10731 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.707A>G p.Y236C 12
43 COSM11066 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.578A>T p.H193L 12
44 COSM10810 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 12
45 COSM10768 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.535C>T p.H179Y 12
46 COSM10779 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.818G>T p.R273L 12
47 COSM10722 TP53 endometrium,NS,carcinoma,endometrioid carcinoma c.853G>A p.E285K 12
48 COSM5154 PTEN endometrium,NS,carcinoma,endometrioid carcinoma c.697C>T p.R233* 12
49 COSM5285 PTEN endometrium,NS,carcinoma,endometrioid carcinoma c.380G>T p.G127V 12
50 COSM5256 PTEN endometrium,NS,carcinoma,endometrioid carcinoma c.76A>C p.T26P 12

Copy number variations for Endometrial Cancer from CNVD:

7 (show top 50) (show all 66)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14799 1 110230418 110236367 Duplication GSTM1 Endometrial cancer
2 16430 1 124300000 247249719 Gain Endometrial cancer
3 16431 1 124300000 247249719 Gain Endometrial cancer
4 16443 1 124300000 247249719 Gain or loss Endometrial cancer
5 30005 1 23900000 28000000 Copy number STMN1 Endometrial cancer
6 38170 10 1 40300000 Gain Endometrial cancer
7 38173 10 1 40300000 Gain or loss Endometrial cancer
8 42809 10 40300000 135374737 Gain Endometrial cancer
9 42810 10 40300000 135374737 Gain or loss Endometrial cancer
10 47133 10 89613174 89718512 Copy number PTEN Endometrial cancer
11 47161 10 89623194 89728531 Loss PTEN Endometrial cancer
12 48495 11 1 52900000 Gain or loss Endometrial cancer
13 55432 11 52900000 134452384 Gain or loss Endometrial cancer
14 61536 12 1 35400000 Gain or loss Endometrial cancer
15 66123 12 25358179 25403863 Amplification KRAS Endometrial cancer
16 75150 13 16000000 114142980 Gain or loss Endometrial cancer
17 82814 14 15600000 106368585 Gain or loss Endometrial cancer
18 89241 15 17000000 100338915 Gain or loss Endometrial cancer
19 97274 16 1 38200000 Gain Endometrial cancer
20 97276 16 1 38200000 Gain or loss Endometrial cancer
21 101463 16 38200000 88827254 Gain or loss Endometrial cancer
22 106793 17 1 22200000 Gain or loss Endometrial cancer
23 108760 17 22200000 78774742 Gain or loss Endometrial cancer
24 119170 18 1 16100000 Gain or loss Endometrial cancer
25 119734 18 16100000 76117153 Gain or loss Endometrial cancer
26 124098 19 1 28500000 Gain or loss Endometrial cancer
27 127175 19 28500000 63811651 Gain or loss Endometrial cancer
28 134355 2 1 93300000 Gain or loss Endometrial cancer
29 146256 2 47483766 47760012 Rearrangement MSH2 Endometrial cancer
30 149784 2 93300000 242951149 Gain or loss Endometrial cancer
31 150416 20 1 27100000 Gain or loss Endometrial cancer
32 151944 20 27100000 62435964 Gain Endometrial cancer
33 151953 20 27100000 62435964 Gain or loss Endometrial cancer
34 157114 21 12300000 46944323 Gain or loss Endometrial cancer
35 160291 22 11800000 49691432 Gain or loss Endometrial cancer
36 163141 22 24376139 24384284 Duplication GSTT1 Endometrial cancer
37 166155 3 1 91700000 Gain or loss Endometrial cancer
38 172027 3 175700000 179000000 Amplification PIK3CA Endometrial cancer
39 175016 3 37009982 37067341 Rearrangement MLH1 Endometrial cancer
40 179466 3 91700000 199501827 Gain or loss Endometrial cancer
41 179984 4 1 50700000 Gain or loss Endometrial cancer
42 187532 4 50700000 191273063 Gain or loss Endometrial cancer
43 200012 5 47700000 180857866 Gain or loss Endometrial cancer
44 203699 6 1 60500000 Gain or loss Endometrial cancer
45 214470 6 60500000 170899992 Gain or loss Endometrial cancer
46 217117 7 1 59100000 Gain or loss Endometrial cancer
47 226563 7 59100000 158821424 Gain or loss Endometrial cancer
48 230833 8 1 45200000 Gain or loss Endometrial cancer
49 240068 8 45200000 146274826 Gain Endometrial cancer
50 240080 8 45200000 146274826 Gain or loss Endometrial cancer

Expression for Endometrial Cancer

Search GEO for disease gene expression data for Endometrial Cancer.

Pathways for Endometrial Cancer